Kiniksa Pharmaceuticals (KNSA)

• Market cap: $2.7B
• 1 day: -1.89%
• 5 days: 0.86%
• 1 month: 9.05%
• 3 months: 28.12%
• 6 months: 58.47%
• Year to date: 82.55%
• 1 year: 44.67%
• 5 years: 109.92%
• 10 years: 86.95%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

Employees: 315

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

50% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 3 (+1) [Q2]

45% more first-time investments, than exits

New positions opened: 48 | Existing positions closed: 33

24% more capital invested

Capital invested by funds: $888M [Q1] → $1.1B (+$214M) [Q2]

7% more funds holding

Funds holding: 175 [Q1] → 188 (+13) [Q2]

5% more repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 62

1.08% less ownership

Funds ownership: 95.15% [Q1] → 94.07% (-1.08%) [Q2]

77% less call options, than puts

Call options by funds: $8.22M | Put options by funds: $36.2M

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $42
• Avg. target: $48
• High target: $54

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Jefferies Roger Song	$54	Buy Maintained	29 Jul 2025
Wells Fargo Eva Fortea Verdejo	$42	Overweight Maintained	9 Jul 2025